| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
iSpecimen Inc. Common Stock$2.68
+0.13 (+5.1%)
F 1Pipeline Score Biotech · Clinical
Market Cap
3.80 M
EPS
-2.20
P/E Ratio
-0.06 $
Value Trade
386.18 K
SEC Financials
Q1 2026Dilution Risk
Revenue
156.01 K
Operating CF
-3.36 M
Total Assets
6.61 M
Total Liabilities
5.80 M
Equity
814.04 K
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
2.82 M
Monthly Burn
1.12 M
Runway
1.5 mo
Burn Trend
SEC Filing
May 18, 2026
Overview
Volume
72.73 K
52 Week Range
0.13 - 3.18
% held by Insiders
0.07 %
% held by Institutions
0.92 %
Enterprise Value
-2.81 M
Total Shares
1.44 M
Short %
16.74 %
Float Shares
1.44 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F1
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 3%
Micro Cap (rank 879 of 905)
Percentile RankiSpecimen Inc. Common Stock has significant pipeline risk (1/100), but cash runway is a concern.
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ISPC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
ISPC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ISPC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ISPC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ISPC Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
ISPC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-ISPC
May 9, 2026iSpecimen Inc. Announces Pricing of Approximately $2.5 Million Private Placement
iSpecimen Inc. has announced a private placement offering priced at approximately $2.5 million, set to close around May 11, 2026. The company will issue 488,281 shares at $5.12 each, with options for pre-funded warrants. Proceeds will be used for working capital, including marketing expenses. The offering is subject to stockholder approval for additional share issuance.
Read more →-ISPC
Feb 6, 2026iSpecimen Announces Milestone 2: System Integration and Marketplace Activation Complete
iSpecimen has announced the successful completion of Milestone 2, which includes the integration of their system and activation of their marketplace. This achievement is expected to enhance their operational capabilities and improve access to biospecimens. The company is optimistic about the future prospects following this milestone.
Read more →-ISPC
Feb 6, 2026iSpecimen Achieves Rapid Procurement Milestone for Influenza Research
iSpecimen has successfully reached a rapid procurement milestone aimed at advancing influenza research. This achievement is expected to significantly enhance the company's capabilities in providing biological samples for research purposes. The milestone underscores iSpecimen's commitment to supporting public health initiatives through improved research resources.
Read more →Competitive Position
How ISPC ranks across every disease it competes inCompetitive Position is a premium feature
See how ISPC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial